Breaking News, Collaborations & Alliances

MedPharm & Palvella Expand Partnership

For developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm announced the expansion of their partnership with Palvella Therapeutics.    To date, MedPharm has employed its specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). MedPharm has also made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study. “Me...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters